Anti-cancer vaccines and related therapy

The anti-cancer vaccine of any one of the preceding claims, wherein the vaccine comprises a DNA or RNA sequence encoding said neoantigen.

The anti-cancer vaccine of any one of the preceding claims, wherein said vaccine is in the form of a plurality of dendritic cells (DCs) that have been pulsed with said at least one peptide comprising the neoantigen and which are capable of presenting said neoantigen to one or more T cells when administered to a subject.

The anti-cancer vaccine of any one of the preceding claims, wherein said neoantigen is an MHC class I restricted peptide.

The anti-cancer vaccine of any one of the preceding claims, wherein said neoantigen is predicted to be presented by MHC class I with a best rank (BR) score of 0.5 or less using the NetMHCpan-4.0 neural network predictor.

The anti-cancer vaccine of any one of the preceding claims, wherein the vaccine comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different neoantigens and/or polynucleotide encoding the different neoantigens.

The anti-cancer vaccine of any one of the preceding claims further comprising at least one adjuvant.

An engineered T cell that recognises a neoantigen encoded by a mutant HR DNA repair gene selected from the group:

• BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation and wherein the T cell is selected from:
• a chimeric antigen receptor T cell (CAR-T), an engineered T cell receptor (TCR) T cell or a neoantigen-reactive T cell (NAR-T).